Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
DMAC
DiaMedica Therapeutics Inc.
DM199 represents a drug-delivery/therapeutic platform with IV administration and ongoing manufacturing development.
|
$291.61M |
$6.75
-0.74%
|
|
AVIR
Atea Pharmaceuticals, Inc.
Atea's lead program comprises antiviral small-molecule therapeutics targeting HCV.
|
$278.13M |
$3.21
-1.23%
|
|
CAPR
Capricor Therapeutics, Inc.
Capricor's lead asset deramiocel is a cell-based therapy, the core product offering of the company.
|
$277.45M |
$6.26
+3.13%
|
|
ACRS
Aclaris Therapeutics, Inc.
Company's focus is on immuno-inflammatory diseases, aligning with Immunology Therapeutics.
|
$277.20M |
$2.42
-5.27%
|
|
DBVT
DBV Technologies S.A.
Viaskin Peanut EPIT patch is a drug-delivery platform; DBV Technologies directly develops and commercializes this patch-based immunotherapy.
|
$275.03M |
$14.53
+1.96%
|
|
TKNO
Alpha Teknova, Inc.
Teknova provides GMP-grade manufacturing for clinical-relevant reagents and custom solutions, aligning with contract manufacturing services.
|
$271.48M |
$4.74
-6.79%
|
|
IMMP
Immutep Limited
Immutep is focused on immunology therapeutics, including LAG-3 modulation for cancer and autoimmune diseases.
|
$266.37M |
$1.83
|
|
BIOA
BioAge Labs, Inc.
BioAge's lead program BGE-102 is an oral small-molecule therapeutic, and APJ agonists are being developed for obesity, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$266.01M |
$7.51
+1.21%
|
|
VNDA
Vanda Pharmaceuticals Inc.
Fanapt and other marketed/potential small-molecule therapies (e.g., Tradipitant) are oral small molecule therapeutics.
|
$264.13M |
$4.34
-2.80%
|
|
LFCR
Lifecore Biomedical, Inc.
Lifecore is a pure-play CDMO focused on sterile injectable drug development and manufacturing.
|
$263.25M |
$6.80
-4.36%
|
|
CADL
Candel Therapeutics, Inc.
CAN-2409 and CAN-3110 are viral vector-based therapies, aligning with gene therapy.
|
$261.54M |
$5.12
-2.01%
|
|
ELDN
Eledon Pharmaceuticals, Inc.
Tegoprubart is an IgG1 monoclonal antibody therapeutic targeting CD40L.
|
$261.08M |
$4.17
-4.36%
|
|
SGMT
Sagimet Biosciences Inc.
Sagimet's lead and second FASN inhibitors (denifanstat, TVB-3567) are oral small-molecule therapeutics, directly aligning with this tag.
|
$259.49M |
$7.84
-2.67%
|
|
ALLO
Allogene Therapeutics, Inc.
Direct product category: off-the-shelf allogeneic CAR-T cell therapies (Allogene's core platform and pipeline).
|
$258.10M |
$1.10
-6.36%
|
|
TRDA
Entrada Therapeutics, Inc.
Entrata's primary value proposition is its Drug Delivery Platform (EEV) enabling intracellular delivery of therapeutics.
|
$257.32M |
$6.62
-2.43%
|
|
INZY
Inozyme Pharma, Inc.
Inozyme focuses on ENPP1 Deficiency, a rare disease, with INZ-701 as a lead therapy, making it a dedicated rare-disease biopharma company.
|
$256.96M |
$4.00
|
|
EDIT
Editas Medicine, Inc.
Core product category: in vivo gene therapy using Editas's gene-editing platform (AsCas12a) delivered via targeted lipid nanoparticles (tLNP).
|
$256.16M |
$2.84
-7.19%
|
|
CNFN
CFN Enterprises Inc.
CNFN's Ranco segment operates as a contract manufacturer/co-packer and white-label producer for clients.
|
$255.19M |
$2.15
|
|
VYGR
Voyager Therapeutics, Inc.
Voyager’s core offerings are gene therapies and gene-delivery platforms, including APOE and tau-targeted approaches.
|
$253.99M |
$4.20
-8.50%
|
|
ARCT
Arcturus Therapeutics Holdings Inc.
Direct product: vaccines pipeline and KOSTAIVE vaccine production and commercialization.
|
$252.22M |
$8.96
-3.66%
|
|
PBYI
Puma Biotechnology, Inc.
Direct oncology biotech core product portfolio with Nerlynx and alisertib being cancer therapies.
|
$250.18M |
$4.92
-2.38%
|
|
LRMR
Larimar Therapeutics, Inc.
Nomlabofusp is a recombinant fusion protein, i.e., a recombinant protein/enzyme therapeutic.
|
$248.43M |
$3.85
-0.90%
|
|
ALMS
Alumis Inc. Common Stock
Alumis is developing oral TYK2 inhibitors (ESK-001 and A-005), a major product category of oral small molecule therapeutics.
|
$248.09M |
$4.53
-0.77%
|
|
HUMA
Humacyte, Inc.
ATEV platform relates to tissue engineering/cell therapy platforms; relevant biotech tag.
|
$246.64M |
$1.50
-5.35%
|
|
ABEO
Abeona Therapeutics Inc.
ZEVASKYN is an autologous cell-based therapy (cell therapy) targeting RDEB wounds.
|
$244.53M |
$4.52
-5.44%
|
|
LYEL
Lyell Immunopharma, Inc.
Lyell’s lead program LYL314 is a CAR-T cell therapy product targeting cancer (CD19/CD20 dual-target), the core business.
|
$244.39M |
$16.32
-1.36%
|
|
ASMB
Assembly Biosciences, Inc.
Assembly Biosciences develops small-molecule antiviral therapeutics, including HSV helicase-primase inhibitors, HDV entry inhibitors, HBV capsid assembly modulators, and NNPI programs.
|
$238.06M |
$31.60
+1.38%
|
|
IMRX
Immuneering Corporation
Atebimetinib (IMM-1-104) is an oral small-molecule therapeutic in clinical trials.
|
$236.07M |
$6.32
-3.73%
|
|
PYXS
Pyxis Oncology, Inc.
Pyxis Oncology is a biotechnology company focused on oncology therapeutics, with MICVO as its lead asset in cancer.
|
$236.02M |
$3.92
+2.76%
|
|
CLLS
Cellectis S.A.
Lead assets UCART22 and UCART20x22 are allogeneic cell therapies (CAR-T) directly developed and manufactured by the company.
|
$235.75M |
$3.29
+0.46%
|
|
FHTX
Foghorn Therapeutics Inc.
Clinical-stage biotech focused on oncology therapies targeting chromatin regulatory system (SMARCA2/BRG1, CBP/EP300, ARID1B degraders), a cancer-focused platform.
|
$234.67M |
$3.47
-17.58%
|
Showing page 13 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
